# US 2015/0148290 A1 · Macrocyclic Modulators of the Ghrelin Receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148290 A1
- Document ID: US20150148290A1
- Status: Published application
- Kind: A1
- Application number: 14/530,311
- Filed: 2014-10-31
- Published: 2015-05-28
- Earliest claimed: 2003-06-18
- Assignees: Ocera Therapeutics, Inc.
- Applicants: Ocera Therapeutics, Inc.
- Inventors: Eric Marsault; Carl St-Louis
- Web page: https://patentgrep.com/patent/US20150148290A1

## CPC

- C07K 5/08: Tripeptides
- A61K 38/06: Tripeptides
- A61K 38/25: Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07C 217/62: linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C07C 271/16: to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 213/64: attached in position 2 or 6
- C07D 273/00: Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 5/0827: {containing heteroatoms different from O, S, or N}
- C07K 5/0812: {and aromatic or cycloaliphatic}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method of treating a gastrointestinal disorder comprising administering to a subject in need thereof an effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the gastrointestinal disorder is characterized by gastrointestinal dysmotility.

### Claim 14 (depends on 12)

The method of claim 12, wherein the gastrointestinal disorder is postoperative ileus, gastroparesis, opioid-induced bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, emesis, constipation-predominant irritable bowel syndrome (IBS), delayed gastric emptying, gastroesophageal reflux disease (GERD), gastric ulcers, or Crohn's disease.

### Claim 15 (depends on 14)

The method of claim 14, wherein the gastrointestinal disorder is gastroparesis.

### Claim 16 (depends on 15)

The method of claim 15, and the gastroparesis is diabetic gastroparesis.

### Claim 17 (depends on 14)

The method of claim 14, wherein the gastrointestinal disorder is postoperative ileus.

### Claim 18

A method of treating a subject suffering from a lack of appetite, suppressed appetite, or a disease or disorder that results in decreased food intake comprising administering to a subject in need thereof an effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the subject has been diagnosed as having cachexia.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cachexia is induced by cancer, cardiac disease, acquired immunodeficiency syndrome (AIDS), or renal disease.

### Claim 21 (depends on 12, 18)

The method of claim 12 or 18, wherein the compound is administered parenterally.

### Claim 22 (depends on 21)

The method of claim 21, wherein the compound is administered intravenously.

### Claim 23 (depends on 21)

The method of claim 21, wherein the compound is administered subcutaneously.

### Claim 24 (depends on 21)

The method of claim 21, wherein the compound is the hydrochloride salt.

### Claim 25

A pharmaceutically acceptable salt of a compound having the structure:
wherein the salt is an amorphous or crystalline form.

### Claim 26 (depends on 25)

The pharmaceutically acceptable salt of claim 25, wherein the salt is a hydrochloride, hydrobromide, or hydroiodide salt.

### Claim 27 (depends on 26)

The pharmaceutically acceptable salt of claim 26, wherein the salt is a hydrochloride salt.
